Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® | MicrobiomeTrials← Back to trialsNCT06298409
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-02-15Est. Completion: 2026-02-28
Enrollment target: 34 participants Locations- Silicon Valley Gastroenterology, Mountain View, California, United States
Other microbiome trials you might be interested in
Pancreatic AdenocarcinomaWeight Loss
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma …
Los Angeles, United StatesEst. completion Oct 14, 2028
Irritable Bowel Syndrome - Diarrhoea
The goal of this clinical trial is to learn if Bifidobacterium. animalis subsp.
Lactis A6 Strain or resveratrol to impr…
Beijing, ChinaCompleted Mar 31, 2025
Recruiting
Irritable Bowel Syndrome (IBS)Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
The goal of this clinical trial is to learn if an herbal supplement called Biocidin REMOVE can clear small intestinal ba…
Baltimore, United StatesEst. completion Dec 31, 2027